Diamyd Medical announced it has shifted its focus from the development of the diabetes therapy Diamyd® to the the development of drug candidates for the treatment of chronic pain....
MannKind Corporation announced that it has confirmed with the U.S. Food and Drug Administration the design of two clinical studies that evaluate the efficacy and safety of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler...
Race car driver Charlie Kimball, the first and only licensed driver with diabetes in the history of the Indy Racing League to race at the highest level of the Series, was nominated this week for the Firestone Tire-iffic Award. He was nominated for capitalizing on his best qualifying effort to run up front and finish 11th in The Honda Indy™ 200 at Mid-Ohio this past Sunday.
Dear Mr. President:
We, the undersigned organizations and individuals, request that you attend the United Nations High-Level Summit on Non-Communicable Diseases (NCD) in September...
Obesity is the main culprit in the worldwide avalanche of type 2 diabetes. But how excess weight drives insulin resistance, the condition that may lead to the disease, is only partly understood. Scientists at Joslin Diabetes Center now have uncovered a new way in which obesity wreaks its havoc, by altering the production of proteins that affect how other proteins are spliced together. Their finding, published in Cell Metabolism, may point toward novel targets for diabetes drugs...
Takeda has resubmitted two New Drug Applications (NDA) to the U.S. Food and Drug Administration (FDA) for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone, approved in 1999, for the treatment of type 2 diabetes, in a single tablet...
The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting reached a decision regarding the New Drug Application, by The Bristol-Myers Squibb Company and AstraZeneca for the investigational compound dapagliflozin for treatment of type 2 diabetes...
The European Commission has approved Novo Nordisk's new prefilled insulin pen – FlexTouch for use in the EU. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) - both modern insulins currently delivered in FlexPen.
FlexTouch, the latest prefilled delivery system from Novo Nordisk, offers a new insulin injection experience for users...
PositiveID Corporation announced that it has successfully created and laboratory-tested a stable and reproducible closed-cycle, continuous glucose sensing system that functions in the human blood fractions that are relevant to glucose analysis in the human body. PositiveID's development of the glucose sensor, which is based on RECEPTORS LLC's ("Receptors") proprietary chemistry platform...
Children with Diabetes (CWD) anounced that it has signed a two year partnership with Novo Nordisk to develop and distribute resources that will help newly diagnosed children with type 1 diabetes adjust to their new lifestyle. Every year approximately 15,600 children and adolescents in the United States are diagnosed with type 1 diabetes...